Clinical Implications of the Oncometabolite Succinate in SDHx-mutation Carriers

Overview

Journal Clin Genet

Specialty Genetics

Date 2019 Apr 13

PMID 30977114

Citations 34

Authors

Karin Eijkelenkamp

Thamara E Osinga

Thera P Links

Anouk N A van der Horst-Schrivers

Affiliations

Soon will be listed here.

Abstract

Succinate dehydrogenase (SDH) mutations lead to the accumulation of succinate, which acts as an oncometabolite. Germline SDHx mutations predispose to paraganglioma (PGL) and pheochromocytoma (PCC), as well as to renal cell carcinoma and gastro-intestinal stromal tumors. The SDHx genes were the first tumor suppressor genes discovered which encode for a mitochondrial enzyme, thereby supporting Otto Warburg's hypothesis in 1926 that a direct link existed between mitochondrial dysfunction and cancer. Accumulation of succinate is the hallmark of tumorigenesis in PGL and PCC. Succinate accumulation inhibits several α-ketoglutarate dioxygenases, thereby inducing the pseudohypoxia pathway and causing epigenetic changes. Moreover, SDH loss as a consequence of SDHx mutations can lead to reprogramming of cell metabolism. Metabolomics can be used as a diagnostic tool, as succinate and other metabolites can be measured in tumor tissue, plasma and urine with different techniques. Furthermore, these pathophysiological characteristics provide insight into therapeutic targets for metastatic disease. This review provides an overview of the pathophysiology and clinical implications of oncometabolite succinate in SDHx mutations.

Citing Articles

The Role of Mitochondrial Solute Carriers SLC25 in Cancer Metabolic Reprogramming: Current Insights and Future Perspectives.

Ahmed A, Iaconisi G, Di Molfetta D, Coppola V, Caponio A, Singh A Int J Mol Sci. 2025; 26(1.

PMID: 39795950 PMC: 11719790. DOI: 10.3390/ijms26010092.

Al Khazal F, Mahadev Bhat S, Zhu Y, de Araujo Correia C, Zhou S, Wilbanks B Cancer Metab. 2024; 12(1):39.

PMID: 39716277 PMC: 11668036. DOI: 10.1186/s40170-024-00369-9.

Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.

He C, Wang Z, Yu J, Mao S, Xiang X Curr Treat Options Oncol. 2024; 25(11):1390-1405.

PMID: 39441520 PMC: 11541409. DOI: 10.1007/s11864-024-01272-7.

Succinate Dehydrogenase and Human Disease: Novel Insights into a Well-Known Enzyme.

Esteban-Amo M, Jimenez-Cuadrado P, Serrano-Lorenzo P, de la Fuente M, Simarro M Biomedicines. 2024; 12(9).

PMID: 39335562 PMC: 11429145. DOI: 10.3390/biomedicines12092050.

A Novel Human SDHA-Knockout Cell Line Model for the Functional Analysis of Clinically Relevant SDHA Variants.

Kent J, Klug L, Heinrich M Clin Cancer Res. 2024; 30(23):5399-5412.

PMID: 39321216 PMC: 11611653. DOI: 10.1158/1078-0432.CCR-24-1601.

References

Semenza G . Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci. 2012; 33(4):207-14. PMC: 3437546. DOI: 10.1016/j.tips.2012.01.005. View

Atlante S, Visintin A, Marini E, Savoia M, Dianzani C, Giorgis M . α-ketoglutarate dehydrogenase inhibition counteracts breast cancer-associated lung metastasis. Cell Death Dis. 2018; 9(7):756. PMC: 6037705. DOI: 10.1038/s41419-018-0802-8. View

Cardaci S, Zheng L, Mackay G, van den Broek N, MacKenzie E, Nixon C . Pyruvate carboxylation enables growth of SDH-deficient cells by supporting aspartate biosynthesis. Nat Cell Biol. 2015; 17(10):1317-26. PMC: 4591470. DOI: 10.1038/ncb3233. View

Varoquaux A, Fur Y, Imperiale A, Reyre A, Montava M, Fakhry N . Magnetic resonance spectroscopy of paragangliomas: new insights into in vivo metabolomics. Endocr Relat Cancer. 2015; 22(4):M1-8. PMC: 4609897. DOI: 10.1530/ERC-15-0246. View

Gill A, Toon C, Clarkson A, Sioson L, Chou A, Winship I . Succinate dehydrogenase deficiency is rare in pituitary adenomas. Am J Surg Pathol. 2014; 38(4):560-6. PMC: 3966922. DOI: 10.1097/PAS.0000000000000149. View

Toledo R, Burnichon N, Cascon A, Benn D, Bayley J, Welander J . Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas. Nat Rev Endocrinol. 2016; 13(4):233-247. DOI: 10.1038/nrendo.2016.185. View

Kunst H, Rutten M, de Monnink J, Hoefsloot L, Timmers H, Marres H . SDHAF2 (PGL2-SDH5) and hereditary head and neck paraganglioma. Clin Cancer Res. 2011; 17(2):247-54. DOI: 10.1158/1078-0432.CCR-10-0420. View

van Hulsteijn L, Dekkers O, Hes F, Smit J, Corssmit E . Risk of malignant paraganglioma in SDHB-mutation and SDHD-mutation carriers: a systematic review and meta-analysis. J Med Genet. 2012; 49(12):768-76. DOI: 10.1136/jmedgenet-2012-101192. View

Kluckova K, Tennant D . Metabolic implications of hypoxia and pseudohypoxia in pheochromocytoma and paraganglioma. Cell Tissue Res. 2018; 372(2):367-378. PMC: 5915505. DOI: 10.1007/s00441-018-2801-6. View

10.

Garrigue P, Bodin-Hullin A, Balasse L, Fernandez S, Essamet W, Dignat-George F . The Evolving Role of Succinate in Tumor Metabolism: An F-FDG-Based Study. J Nucl Med. 2017; 58(11):1749-1755. PMC: 6944169. DOI: 10.2967/jnumed.117.192674. View

11.

Imperiale A, Moussallieh F, Roche P, Battini S, Cicek A, Sebag F . Metabolome profiling by HRMAS NMR spectroscopy of pheochromocytomas and paragangliomas detects SDH deficiency: clinical and pathophysiological implications. Neoplasia. 2015; 17(1):55-65. PMC: 4309730. DOI: 10.1016/j.neo.2014.10.010. View

12.

Chan D, Sutphin P, Nguyen P, Turcotte S, Lai E, Banh A . Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med. 2011; 3(94):94ra70. PMC: 3683134. DOI: 10.1126/scitranslmed.3002394. View

13.

Roman-Gonzalez A, Zhou S, Ayala-Ramirez M, Shen C, Waguespack S, Habra M . Impact of Surgical Resection of the Primary Tumor on Overall Survival in Patients With Metastatic Pheochromocytoma or Sympathetic Paraganglioma. Ann Surg. 2017; 268(1):172-178. DOI: 10.1097/SLA.0000000000002195. View

14.

Jasim S, Suman V, Jimenez C, Harris P, Sideras K, Burton J . Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma. Endocrine. 2017; 57(2):220-225. DOI: 10.1007/s12020-017-1359-5. View

15.

Ploumakis A, Coleman M . OH, the Places You'll Go! Hydroxylation, Gene Expression, and Cancer. Mol Cell. 2015; 58(5):729-41. DOI: 10.1016/j.molcel.2015.05.026. View

16.

Koh J, Ahn S, Kim H, Kim B, Sung T, Kim Y . Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma. PLoS One. 2017; 12(11):e0187398. PMC: 5678867. DOI: 10.1371/journal.pone.0187398. View

17.

Castro-Vega L, Letouze E, Burnichon N, Buffet A, Disderot P, Khalifa E . Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. Nat Commun. 2015; 6:6044. PMC: 4354166. DOI: 10.1038/ncomms7044. View

18.

Baysal B, Ferrell R, Willett-Brozick J, Lawrence E, Myssiorek D, Bosch A . Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 2000; 287(5454):848-51. DOI: 10.1126/science.287.5454.848. View

19.

Maniam P, Zhou K, Lonergan M, Berg J, Goudie D, Newey P . Pathogenicity and Penetrance of Germline Variants in Pheochromocytoma and Paraganglioma (PPGL). J Endocr Soc. 2018; 2(7):806-816. PMC: 6030830. DOI: 10.1210/js.2018-00120. View

20.

Her Y, Nelson-Holte M, Maher 3rd L . Oxygen concentration controls epigenetic effects in models of familial paraganglioma. PLoS One. 2015; 10(5):e0127471. PMC: 4436181. DOI: 10.1371/journal.pone.0127471. View